Diagnostic and Prognostic Value of Serum Omentin-1 in Sepsis: A Prospective Study in Critically Ill Patients
Irene Karampela,
Natalia G. Vallianou,
Dimitrios Tsilingiris,
Gerasimos Socrates Christodoulatos,
Georgios Antonakos,
Ioanna Marinou,
Evaggelos Vogiatzakis,
Apostolos Armaganidis,
Maria Dalamaga
Affiliations
Irene Karampela
Second Department of Critical Care, Attikon General University Hospital, Medical School, National and Kapodistrian University of Athens, 12462 Athens, Greece
Natalia G. Vallianou
First Department of Internal Medicine, Evangelismos General Hospital, 10676 Athens, Greece
Dimitrios Tsilingiris
First Department of Internal Medicine, University Hospital of Alexandroupolis, Democritus University of Thrace, 68100 Alexandroupolis, Greece
Gerasimos Socrates Christodoulatos
Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
Georgios Antonakos
Laboratory of Clinical Biochemistry, Attikon General University Hospital, Medical School, National and Kapodistrian University of Athens, 12462 Athens, Greece
Ioanna Marinou
Laboratory of Microbiology, Sotiria Athens General Hospital, 11527 Athens, Greece
Evaggelos Vogiatzakis
Laboratory of Microbiology, Sotiria Athens General Hospital, 11527 Athens, Greece
Apostolos Armaganidis
Second Department of Critical Care, Attikon General University Hospital, Medical School, National and Kapodistrian University of Athens, 12462 Athens, Greece
Maria Dalamaga
Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
Background and Objectives: Omentin-1, also known as intelectin-1, is a novel adipokine with anti-inflammatory activities implicated in inflammatory diseases and sepsis. We aimed to explore serum omentin-1 and its kinetics in critically ill patients early in sepsis and its association with severity and prognosis. Materials and Methods: Serum omentin-1 was determined in 102 critically ill patients with sepsis during the first 48 h from sepsis onset and 1 week later, and in 102 age- and gender-matched healthy controls. The outcome of sepsis at 28 days after enrollment was recorded. Results: Serum omentin-1 at enrollment was significantly higher in patients compared to controls (763.3 ± 249.3 vs. 451.7 ± 122.3 μg/L, p p n = 42) had higher omentin-1 compared to those with sepsis (n = 60) at enrollment (877.9 ± 241.2 vs. 683.1 ± 223.7 μg/L, p p = 0.007). Furthermore, nonsurvivors (n = 30) had higher omentin-1 at sepsis onset (952.1 ± 248.2 vs. 684.6 ± 204.7 μg/L, p p p = 0.01, and 39.4 ± 34.3% vs. 13.3 ± 18.1%, p p = 0.01 and HR: 2.15, 95% C.I. 1.43–3.22, p Conclusions: Serum omentin-1 is increased in sepsis, while higher levels and lower kinetics during the first week of sepsis are associated with the severity and 28-day mortality of sepsis. Omentin-1 may be a promising biomarker of sepsis. However, more studies are needed to explore its role in sepsis.
